This is a preview of subscription content, log in via an institution to check access.
REFERENCE
Doan QV, Yu H, Plauschinat CA, Hollenberg NK.Cost effectiveness of valsartan 320 mg vs valsartan 160 mg to delay nephropathy progression in patients with type 2 diabetes and hypertension. Journal of Clinical Hypertension 10 (Suppl. A): 102, No. 5, May 2008
Ly D, Fu AZ, Hebert C.Cost effectiveness analysis of a hypertension management program in patients with type 2 diabetes. Journal of Clinical Hypertension 10 (Suppl. A): 114, No. 5, May 2008
Rights and permissions
About this article
Cite this article
Hypertension management in the spotlight. Pharmacoecon. Outcomes News 554, 4 (2008). https://doi.org/10.2165/00151234-200805540-00007
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200805540-00007